Eye On Quality And Price, Govt Plans Single Platform To Source Medicines

MUMBAI : The government plans to create a common platform to handle procurement of medicines for all Central government agencies, including the Central Government Health Scheme (CGHS), institutions and public sector undertakings. The objective is to reap the benefits of a bulk purchase through a common mechanism, where drugs will be of uniform quality and pricing, across the country.

Overall, Central and state governments’ drug procurement is estimated to be Rs 22,000 crore annually, or about 15% of the total pharma market.

At present, the same medication may be purchased by different government organisations and separate ministries — health and chemicals & fertilisers, at different prices. Significantly, the move could also prevent the practice of over-billing by certain pharma companies, and offer high-value critical products at a reduced price, resulting in huge savings for the government, sources told TOI.

A major part of the government procurement is used for schemes and institutions including Jan aushadhi, CGHS, AIIMS and Employees’ State Insurance Corporation. The mechanism being discussed is only for procurement by the Centre, as states have their independent system in place.

The matter has been discussed by both ministries — health & family welfare and Chemicals & Fertilisers with presentations made by entities including GeM (Government e-Market Place), sourcesadded. Among the possible entities which could be roped in include GeM and Indian Drugs and Pharmaceuticals Ltd. Further, for sourcing products like vitamins, basic antibiotics and paracetamol preference could be given to micro, small and medium enterprises, sources said.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre